Related Experiment Videos
Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment
1The Ludwig Institute for Cancer Research and Department of Oncology, Royal Free and University College London Medical School, 91 Riding House Street, London W1W 7BS, UK. rstein@ludwig.ucl.ac.uk
Abstract:
The phosphoinositide 3-kinases (PI3-kinases) are a family of lipid kinases that have a key role in the regulation of many cellular processes including proliferation, survival, carbohydrate metabolism, and motility. There is now strong evidence that some members of the PI3-kinase family have an important role in cancer. Emerging evidence for functional specialisation of PI3-kinase isoforms suggests that isoform selective inhibitors, in contrast to the existing non-selective inhibitors wortmannin and LY294002, may prove to be useful anticancer drugs.
Insights
Phosphoinositide 3-kinases (PI3-kinases) regulate cell functions and are implicated in cancer. Isoform-selective PI3-kinase inhibitors show promise as targeted anticancer drugs, offering an alternative to non-selective inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Phosphoinositide 3-kinases (PI3-kinases) are crucial lipid kinases involved in fundamental cellular processes.
- These processes include cell proliferation, survival, metabolism, and motility.
- Aberrant PI3-kinase activity is increasingly recognized as a significant factor in cancer development.
Purpose of the Study:
- To explore the role of PI3-kinase family members in cancer.
- To investigate the potential of isoform-selective PI3-kinase inhibitors as anticancer therapeutics.
Main Methods:
- Review of existing scientific literature on PI3-kinases and cancer.
- Analysis of emerging evidence for functional specialization among PI3-kinase isoforms.
Main Results:
- Strong evidence supports the involvement of specific PI3-kinase members in oncogenesis.
- Emerging data suggests functional differences between PI3-kinase isoforms.
Conclusions:
- Targeting specific PI3-kinase isoforms may offer a more precise therapeutic strategy than using non-selective inhibitors like wortmannin and LY294002.
- Isoform-selective PI3-kinase inhibitors represent a promising avenue for novel anticancer drug development.